Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 14/20 | 0.55 |
| ▸ | CDK2 | P24941 | 14/20 | 0.55 |
| ▸ | CDK4 | P11802 | 9/20 | 0.55 |
| ▸ | CCND1 | P24385 | 9/20 | 0.55 |
| ▸ | CCND3 | P30281 | 9/20 | 0.55 |
| ▸ | CDK6 | Q00534 | 9/20 | 0.55 |
| ▸ | CDK1 | P06493 | 9/20 | 0.55 |
| ▸ | CCNB1 | P14635 | 9/20 | 0.55 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.55 |
| ▸ | CDK7 | P50613 | 4/20 | 0.55 |
| ▸ | CDK9 | P50750 | 4/20 | 0.55 |
| ▸ | CCNH | P51946 | 4/20 | 0.55 |
| ▸ | MNAT1 | P51948 | 4/20 | 0.55 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22977326 | 0.88 | CCNE1 (0.67) | CCNE1CDK2CDK4CCND1CCND3 | |
| SCHEMBL22977318 | 0.87 | CCNE1 (0.54) | CCNE1CDK2CDK4CCND1CCND3 | |
| SCHEMBL22977439 | 0.85 | CCNE1 (0.54) | CCNE1CDK2CDK4CCND1CCND3 | |
| SCHEMBL22976957 | 0.84 | CCNE1 (0.55) | CCNE1CDK2CDK4CCND1CCND3 | |
| SCHEMBL27213293 | 0.84 | CCNE1 (0.54) | CCNE1CDK2CDK4CCND1CCND3 | |
| SCHEMBL27213249 | 0.84 | CCNE1 (0.54) | CCNE1CDK2CDK4CCND1CCND3 | |
| SCHEMBL30906775 | 0.84 | CCNE1 (0.54) | CCNE1CDK2CDK4CCND1CCND3 | |
| SCHEMBL27213114 | 0.82 | CCNE1 (0.52) | CCNE1CDK2CDK4CCND1CCND3 | |
| SCHEMBL30906838 | 0.82 | CCNE1 (0.52) | CCNE1CDK2CDK4CCND1CCND3 | |
| SCHEMBL25434669 | 0.81 | CCNE1 (0.52) | CCNE1CDK2CDK4CCND1CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243183-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2025-07-31 | — | — | US | disclosed |
| US-12312331-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2025-05-27 | — | — | US | disclosed |
| CN-116348458-A | Imidazolylpyrimidinylamine compounds as CDK2 inhibitors | 因赛特公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20230024173-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2023-01-26 | — | — | US | disclosed |
| US-20230024173-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2023-01-26 | — | — | US | disclosed |
| US-11427567-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2022-08-30 | — | — | US | disclosed |
| EP-4013750-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | Incyte Corporation (US) | 2022-06-22 | — | — | EP | disclosed |
| WO-2021030537-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030537-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION (US) | 2021-02-18 | — | — | WO | disclosed |
| US-20210047294-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2021-02-18 | — | — | US | disclosed |
| US-20210047294-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312331-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | CDK2, CDK4, CDK2AP2 | CCNE1 43/4885CDK2 1/4885CDK4 2/4885 |
| US-11427567-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | CDK2, CDK4, CDK2AP2 | CCNE1 43/4885CDK2 1/4885CDK4 2/4885 |
| US-20210047294-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK4, CDK2AP2 | CCNE1 43/4885CDK2 1/4885CDK4 2/4885 |
| US-20230024173-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK4, CDK2AP2 | CCNE1 43/4885CDK2 1/4885CDK4 2/4885 |
| US-20250243183-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK4, CDK2AP2 | CCNE1 43/4885CDK2 1/4885CDK4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.